There is no global hair relaxer settlement paying claimants as of October 2026. The cases remain in pretrial litigation in MDL No.
3060, a group of similar federal lawsuits coordinated before one judge for pretrial steps. That status decides what claimants can do now. You cannot file a claim for payment yet, but you can track court deadlines and preserve records that support a future claim.
Official resources:
- Explore the official data from Uscourts — Use this primary source to review the underlying data.
- Read the official notice from Aboutlawsuits — Use this primary source to verify the official announcement.
Table of Contents
- How big is the federal case?
- Why are 2027 bellwether trials important?
- What injuries and products are claimed?
- What should potential claimants save now?
How big is the federal case?
The federal litigation is large and still growing. According to the U.S. Judicial Panel on Multidistrict Litigation in its October 1, 2026 statistics report, MDL No. 3060 had 12,381 pending actions and 16,828 total actions.
The cases are coordinated before Judge Mary M. Rowland in the Northern District of Illinois. Coordination does not combine injury claims into one class payout. Each claimant must still show product use, diagnosis, and a link between them. Scale matters because it affects court scheduling, evidence testing, and leverage, not individual award size.
Why are 2027 bellwether trials important?
Bellwether trials are test trials using a small set of cases. Judge Rowland ordered the first federal bellwether trial against L'Oréal USA to begin Sept. 7, 2027. Five bellwether cases were selected to test evidence and valuation before any settlement talks.
The outcomes often shape settlement ranges. A strong plaintiff verdict can raise offers, while defense wins can lower them. According to AboutLawsuits.com in its October 2026 litigation update, no court-approved administrator, payout matrix, or verdict currently sets payments. Watch trial dates, rulings on expert proof, and any court order about settlement talks.
What injuries and products are claimed?
The lawsuits allege regular chemical relaxer use caused uterine cancer, ovarian cancer, uterine fibroids requiring surgery, and endometriosis. The claims focus principally on Black women and girls who received heavy marketing for products such as Dark & Lovely. The concern grew after a large federal study. According to the National Institutes of Health in its October 2022 news release, a Sister Study of 33,497 U.S. women found frequent chemical straightener use, more than four times per year, was associated with more than double the uterine cancer risk versus nonuse. That finding supports study of risk, but it does not prove any one person's cancer came from relaxers.
State enforcement adds another track. Arizona Attorney General Kris Mayes filed a consumer-fraud lawsuit on Sept. 10, 2026 against L'Oréal USA, L'Oréal S.A. and SoftSheen-Carson. It is described as the first state action and seeks penalties, restitution, and cancer warnings or removal. A separate federal proposal to ban formaldehyde and formaldehyde-releasing chemicals in hair smoothing products missed its Dec. 31, 2025 action date, leaving no federal ban in effect.
What should potential claimants save now?
Any future payout would turn on injury type, causation proof, and documented exposure. Keep records that tie products, timing, and care together.
Courts and lawyers give more weight to dated papers than memory alone. Save product names, dates and places of use or purchase, salon records, receipts, photos of packaging, diagnosis reports, surgery records, pathology results, and treatment dates. Track filing deadlines for your state and keep a list of doctors, hospitals, and pharmacies with contact dates.
- Write down each relaxer brand, how often you used it, and the years used
- Keep receipts, salon cards, loyalty records, and empty-box or label photos
- Store pathology, imaging, surgery, and prescription records in one folder
- Note when symptoms began and when you first received each diagnosis